Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_assertion type Assertion NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_head.
- NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_assertion description "[Recently, several new and specific thymidylate synthase inhibitors that occupy the folate binding site, including Tomudex(R), BW1843U89, and Thymitaq, have demonstrated therapeutic activity in patients with advanced cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_provenance.
- NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_assertion evidence source_evidence_literature NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_provenance.
- NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_assertion SIO_000772 9565579 NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_provenance.
- NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_assertion wasDerivedFrom befree-20140225 NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_provenance.
- NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_assertion wasGeneratedBy ECO_0000203 NP604993.RA3b-2lOR99KeKzO1segdOhwHjiY8C56uXC-G_MSn3Dxc130_provenance.